1. Finland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Orion Oyj

Orion Oyj

ORINF
Orion OyjUS flagOther OTC
82.75
USD
- -
- -
11.66BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.14
7.22
7.21
7.63
7.35
6.95
7.48
7.67
7.41
9.54
8.48
10.98
13.43
11.92
Basic EPS, GAAP
1.46
1.5
1.48
1.77
1.61
2.35
1.43
1.57
1.38
2.49
1.54
2.35
3.56
2.69
Free Cash Flow per Basic Share
1.01
1.71
1.5
1.43
1.08
1.17
1.67
1.84
0.93
2.57
0.02
1.47
1.56
1.55
Dividend per Share
1.3
1.25
1.3
1.31
1.55
1.45
1.5
1.5
1.5
1.5
1.6
1.62
1.64
1.63
Book Value per Share
3.63
3.61
4.17
4.54
4.81
5.47
5.53
5.6
5.49
6.5
6.43
7.19
9.13
6.54
Tangible Book Value per Share
3.14
3.21
3.82
4.18
4.46
5.04
5.18
4.9
4.83
5.1
4.92
5.91
7.8
5.22
Basic Weighted Avg Shares
141
141
141
141
141
141
141
141
141
141
140
140
141
141
Sales/Revenue/Turnover
1,007
1,015
1,016
1,074
1,034
978
1,051
1,078
1,041
1,341
1,190
1,542
1,890
1,677
Operating Margin (%)
26.27
26.75
26.36
27.22
27.44
25.69
23.94
25.64
22.83
32.54
22.29
26.88
33.29
28.46
Depreciation Expense
38
40
42
41
42
42
56
56
46
48
52
93
57
- -
Net Income, GAAP
206
211
208
249
226
330
200
220
194
350
217
330
500
378
Effective Tax Rate (%)
21.89
21.14
20.66
19.91
21.1
20.53
20.14
20.98
20.02
20.62
20.26
20.14
20.31
20.18
Profit Margin (%)
20.48
20.81
20.5
23.19
21.87
33.79
19.07
20.4
18.62
26.07
18.22
21.39
26.48
22.54
Working Capital
432
438
441
461
441
414
412
530
481
603
561
742
784
467
LT Debt
233
210
178
150
150
1
7
106
105
197
171
297
115
136
Total Equity
514
515
595
641
680
773
779
731
748
908
890
1,005
1,284
920
Return on Invested Capital (%)
28.94
28.11
27.68
29.49
27.33
22.6
23.26
26.58
22.16
34.67
18.9
26.92
33.32
33.47
Return on Capital (%)
29.6
28.51
27.97
32.26
28.35
38.16
23.67
26.23
21.93
34.95
19.82
27.54
34.62
33.34
Return on Common Equity (%)
40.43
41.42
37.99
40.61
34.36
45.65
25.9
28.13
24.89
41.5
23.88
34.5
43.6
44.71

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
30
30
182
LT Borrowings
291
- -
- -
LT Finance Leases
6
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
141
141
141
Market Capitalization
6,615
6,335
5,805

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,016
1,084
1,008
Cash, Cash Equivalents & STI
206
259
184
Accounts Receivable, Net
255
288
252
Inventories
419
433
442
Total Current Liabilities
274
278
541
Payables & Accruals
- -
- -
- -
ST Debt
30
30
182
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.46%
12.49%
27.81%
Free Cash Flow
935.18%
1,864.03%
6.15%
Net Income, GAAP
16.12%
26.86%
51.65%
Sales/Revenue/Turnover
7.29%
13.25%
22.5%
Total Cash Common Dividend
- -
- -
1.36%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
308
328
471
434
1,542
2025
355
416
695
- -
1,890
2026
418
522
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.31
0.37
1.14
0.52
2.35
2025
0.44
0.59
1.85
- -
3.56
2026
0.64
1
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.81
- -
0.81
1.62
2025
- -
0.83
0.82
- -
1.64
2026
- -
0.91
- -
- -
- -

Company Description

APIChatGPT
CEO
Aino Anna Liisa Hurme
Full Time Employees
3,882
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Orionintie 1 Espoo UU Finland 02200
IPO Date
May 28, 2013
Website
orionpharma.com
Similar Companies
Gland Pharma Limited (GLAND.NS)
Bristol-Myers Squibb Company (0R1F.L)
Aurora Optoelectronics Co.,Ltd. (600666.SS)
BCWORLD PHARM. Co., Ltd. (200780.KQ)
Fangzhou Inc. (6086.HK)
Mayne Pharma Group Limited (MAYNF)
Business
Orion Oyj is a Finnish pharmaceutical company specializing in the development, manufacturing, and marketing of human and veterinary medicines, active pharmaceutical ingredients, and diagnostic kits. Its product portfolio includes prescription drugs targeting oncology, central nervous system, cardiovascular, respiratory, urological diseases, and hormone therapies, alongside consumer health and generic pharmaceuticals. Key products encompass the Easyhaler® inhalation portfolio, entacapone products marketed in Japan, and the prostate cancer drug Nubeqa®, for which Orion receives milestone payments. The company operates globally with a strong presence in Finland and international markets. Founded in 1917 and headquartered in Espoo, Finland, Orion continues to expand its R&D capabilities with a new Biologics R&D Centre in Cambridge, UK, and has entered into exclusive licensing agreements, notably with MSD for global rights related to specific pipeline assets. In 2025, Orion has upgraded its full-year financial outlook, anticipating net sales between EUR 1.82 billion and EUR 1.9 billion and operating profit between EUR 590 million and EUR 670 million, driven by higher-than-expected product sales, royalty income, and the receipt of a EUR 180 million milestone payment linked to Nubeqa® sales. Operational changes include strategic reorganizations in Turku and the termination of certain development programs, alongside expanded collaborations and licensing agreements aimed at reinforcing its innovative medicines pipeline. Orion focuses on both continuing growth in its branded pharmaceuticals division and slight growth in its animal health and generics businesses, reflecting a diversified approach to the pharmaceutical industry.

Company News

APIChatGPT

  • seekingalpha.com

    Orion Oyj (ORINF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Orion Oyj (ORINF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Orion Oyj (ORINF) Q4 2025 Earnings Call Transcript

  • globenewswire.com

    Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

  • seekingalpha.com

    Orion Oyj (ORINF) Q3 2025 Earnings Call Transcript

  • seekingalpha.com

    Orion Oyj (ORINF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    ORION Holdings Corp. (ORINF) Q1 2025 Earnings Call Transcript

  • seekingalpha.com

    ORION Holdings Corp. (ORINF) Q3 2024 Earnings Call Transcript

  • zacks.com

    Orion OYJ (ORINY) Is a Great Choice for 'Trend' Investors, Here's Why

  • zacks.com

    Is Orion OYJ (ORINY) a Solid Growth Stock? 3 Reasons to Think "Yes"

  • seekingalpha.com

    ORION Holdings Corp. (ORINF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    ORION Holdings Corp. (ORINF) Q1 2024 Earnings Call Transcript

  • seekingalpha.com

    Orion Oyj (ORINF) Q4 2023 Earnings Call Transcript